Evidence map›Paper›PMID 33924826›Full record

ArticleGenes2021

Evaluation of RT-qPCR and Loop-Mediated Isothermal Amplification (LAMP) Assays for the Detection of SARS-CoV-2 in Argentina.

María Dolores Fellner, Romina Bonaventura, Jorge Basiletti, Martín Avaro, Estefanía Benedetti, Ana Campos, María Elena Dattero, Mara Russo, Sara Vladmirsky, Viviana Molina and 5 more

Open access · goldAbstract readComparative StudyEvaluation Study
In one paragraph

Article in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

María Dolores FellnerServicio de Virus Oncogénicos, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Romina BonaventuraServicio de Neurovirosis, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Jorge BasilettiServicio de Virus Oncogénicos, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Martín AvaroServicio de Virosis Respiratorias, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Estefanía BenedettiServicio de Virosis Respiratorias, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Ana CamposServicio de Virosis Respiratorias, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
María Elena DatteroServicio de Virosis Respiratorias, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Mara RussoServicio de Virosis Respiratorias, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Sara VladmirskyServicio de Hepatitis Virales, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Viviana MolinaInstituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Lucía IrazuUnidad de Evaluación de Métodos de Diagnóstico y Estadística Aplicada, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Marcelo A RodriguezUnidad de Evaluación de Métodos de Diagnóstico y Estadística Aplicada, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.ORCID 0000-0002-9037-9979
Andrea PontorieroServicio de Virosis Respiratorias, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Daniel M CisternaServicio de Neurovirosis, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Elsa G BaumeisterServicio de Virosis Respiratorias, Departamento de Virología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires 1282AFF, Argentina.
Administración Nacional de Laboratorios e Institutos de Salud · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our aim was to evaluate the analytical and clinical performance of the SARS-CoV-2 molecular detection kits used in Argentina. Nine real-time reverse-transcription polymerase chain reaction (RT-qPCR) and three reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assays were evaluated using the World Health Organization (WHO) recommended test as reference method. A secondary standard calibrated for the E, N and RdRp genes against the Pan American Health Organization-World Health Organization-International Standard was used to calculate the limit of detection (LoD). A panel of artificial clinical samples, 32 positive and 30 negative for SARS-CoV-2, were analyzed to estimate the kappa concordance (κ) and the diagnostic performance. Differences among the LoD values for the target genes amplified by each kit were >1 log copies/reaction. The κ for the RT-qPCR kits was greater than 0.9, whereas that for the RT-LAMP assays ranged from 0.75 to 0.93. The clinical performance of RT-qPCR kits showed 100% specificity and high sensitivity, although with variations according to the gene analyzed. The E and N genes provided greater clinical sensitivity, whereas the RdRp gene increased the clinical specificity. The RT-LAMP assays revealed a variable diagnostic performance. The information provided can be useful to choose the most appropriate diagnostic test and may contribute to the establishment of a consensus in the diagnosis of SARS-CoV-2 in Argentina and the region.

Indexed as

ArgentinaCalibrationCOVID-19 Nucleic Acid TestingHumansLimit of DetectionMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesReal-Time Polymerase Chain ReactionSARS-CoV-2RT-LAMPRT-qPCRSARS-CoV-2

Identifiers

PMID33924826
PMCPMC8146092
OpenAlexW3157843865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.